Continuous renal replacement therapy for safe and adequate voriconazole intravenous treatment: Enough reason to be confident?

Critical Care

Volumn 19, Issue 1, 2015, Pages

  Honore, Patrick M ^a   Jacobs, Rita ^a   Hendrickx, Inne ^a   De Waele, Elisabeth ^a   Van Gorp, Viola ^a   Spapen, Herbert D ^a  

^a UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CYCLODEXTRIN; SULFOBUTYLETHER BETA CYCLODEXTRIN SODIUM; UNCLASSIFIED DRUG; VORICONAZOLE; ANTIFUNGAL AGENT; BETA CYCLODEXTRIN DERIVATIVE;

BIOACCUMULATION; CONTINUOUS HEMOFILTRATION; CONTINUOUS RENAL REPLACEMENT THERAPY; CREATININE CLEARANCE; DIFFUSION BASED CONTINUOUS RENAL REPLACEMENT THERAPY; DRUG CONTRAINDICATION; DRUG ELIMINATION; DRUG SAFETY; HUMAN; LETTER; MEMBRANE PERMEABILITY; MOLECULAR WEIGHT; MYCOSIS; PRIORITY JOURNAL; SYSTEMIC DISEASE; THERMODYNAMICS; KIDNEY FAILURE, CHRONIC; MALE; PROCEDURES; RENAL REPLACEMENT THERAPY; THERAPY;

ANTIFUNGAL AGENTS; BETA-CYCLODEXTRINS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; RENAL REPLACEMENT THERAPY; THERAPEUTICS; VORICONAZOLE;

EID: 85019241990     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/s13054-015-0946-1     Document Type: Letter

References (3)

1. von Mach MA, Burhenne J, Weilemann LS. Accumulation of the solvent vehicle sulphobutylether beta cyclodextrin sodium in critically ill patients treated with intravenous voriconazole under renal replacement therapy. BMC Clin Pharmacol. 2006;6:6.
2. Luke DR, Tomaszewski K, Damle B, Schlamm HT. Review of the basic and clinical pharmacology of sulfobutylether-beta-cyclodextrin (SBECD). J Pharm Sci. 2010;99:3291-301.
3. Kiser TH, Fish DN, Aquilante CL, Rower JE, Wempe MF, MacLaren R, et al. Evaluation of sulfobutylether-β-cyclodextrin (SBECD) accumulation and voriconazole pharmacokinetics in critically ill patients undergoing continuous renal replacement therapy. Crit Care. 2015;19:32.